Empirical Article (CE Activity)
A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder
Article first published online: 5 FEB 2013
Copyright © 2013 Wiley Periodicals, Inc.
International Journal of Eating Disorders
Volume 46, Issue 3, pages 239–245, April 2013
How to Cite
McElroy, S. L., Guerdjikova, A. I., Blom, T. J., Crow, S. J., Memisoglu, A., Silverman, B. L. and Ehrich, E. W. (2013), A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder. Int. J. Eat. Disord., 46: 239–245. doi: 10.1002/eat.22114
- Issue published online: 11 MAR 2013
- Article first published online: 5 FEB 2013
- Manuscript Revised: 25 DEC 2012
- Alkermes. Grant Number: NCT01098435
- binge eating disorder;
- opioid receptor antagonist
To assess preliminarily the effectiveness of a novel opioid antagonist, ALKS-33, in binge eating disorder (BED).
In this randomized, placebo-controlled, flexible dose, proof-of-concept trial, 62 outpatients with BED and obesity received ALKS-33 (N = 26) or placebo (N = 36) for 6 weeks. Outcome measures of binge eating, body weight, and eating pathology were assessed.
A large decrease in binge eating episode frequency was observed following both ALKS-33 and placebo treatment. There was no significant difference between treatment groups in binge eating episode frequency or any other measure of binge eating, body weight, or eating pathology.
In this preliminary proof-of-concept study in BED, ALKS-33 did not separate from placebo. Although a failed trial cannot be excluded, the finding is consistent with earlier observations in bulimia nervosa with other opioid antagonists and suggests ALKS-33, at least when administered daily for 6 weeks, may not be efficacious for BED. © 2013 by Wiley Periodicals, Inc. (Int J Eat Disord 2013)